99mTc-MIP-1404用于早期生化复发前列腺癌的SPECT/CT显像及后续PSMA放射引导手术的可行性:9例病例系列
这项病例系列评估了99mTc-MIP-1404用于前列腺特异性膜抗原(PSMA)放射引导手术(RGS)在复发性前列腺癌中的可行性。9例PET/CT显示PSMA阳性病灶的患者接受了99mTc-MIP-1404(中位数747 MBq)注射,随后行SPECT/CT和RGS。结果显示PSMA-RGS在所有患者中均识别出淋巴结转移,较PET/CT额外发现2个病灶,6/9例患者术后前列腺特异性抗原下降。
要点
- 9例生化复发前列腺癌患者接受99mTc-MIP-1404后行SPECT/CT与PSMA-RGS。
- PET/CT检出17个PSMA阳性病灶,SPECT/CT可见9个(52.9%)。
- PSMA-RGS在所有患者中识别出淋巴结转移,较PET/CT多发现2个病灶。
核心结论
- 99mTc-MIP-1404引导的PSMA-RGS在所有患者中识别出淋巴结转移,较PET/CT额外发现2个病灶。
- 9例患者中6例(67%)术后前列腺特异性抗原值下降。
研究设计与样本
- 病例系列研究,纳入9例复发性前列腺癌患者。
- 患者PET/CT显示PSMA阳性病灶,接受99mTc-MIP-1404(中位数747 MBq;四分位距710-764 MBq)注射。
- 注射后17.2小时(四分位距16.9-17.5小时)行SPECT/CT,22.3小时(四分位距20.8-24.0小时)后行RGS。
主要发现
- PET/CT检出17个PSMA阳性病灶(中位短轴直径4 mm;四分位距3-6 mm;中位SUVmax 8.9;四分位距5.2-12.6)。
- 17个病灶中9个(52.9%)在SPECT/CT上可见(中位SUVmax 13.8;四分位距8.0-17.9)。
- 除2个病灶外,所有PET/CT阳性表现均显示术中计数率高于背景水平(中位计数31;四分位距17-89),且均为淋巴结转移。
- PSMA-RGS较PET/CT额外识别出2个转移灶。
- 9例患者中6例(67%)术后前列腺特异性抗原值下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This case series evaluated the feasibility of prostate-specific membrane antigen (PSMA)-radioguided surgery (RGS) with 99mTc-MIP-1404 in recurrent prostate cancer. Methods: Nine patients with PSMA-positive lesions on PET/CT received 99mTc-MIP-1404 (median, 747 MBq; interquartile range [IQR], 710-764 MBq) 17.2 h (IQR, 16.9-17.5 h) before SPECT/CT and 22.3 h (IQR, 20.8-24.0 h) before RGS. Results: Seventeen PSMA-positive lesions were detected on PET/CT (median short-axis diameter, 4 mm; IQR, 3-6 mm; median SUVmax, 8.9; IQR, 5.2-12.6). Nine of 17 (52.9%) were visible on SPECT/CT (median SUVmax, 13.8; IQR, 8.0-17.9). Except for 2 foci, all PET/CT-positive findings demonstrated intraoperative count rates above the background level (median count, 31; IQR, 17-89) and were lymph node metastases. Moreover, PSMA-RGS identified 2 additional metastases compared with PET/CT. Prostate-specific antigen values decreased after RGS in 6 of 9 patients (67%). Conclusion: PSMA-RGS with 99mTc-MIP-1404 identified lymph node metastases in all patients, including 2 additional lesions compared with PET/CT.
引用
- Koehler D, Sauer M, Klutmann S, et al. Feasibility of 99mTc-MIP-1404 for SPECT/CT Imaging and Subsequent PSMA-Radioguided Surgery in Early Biochemically Recurrent Prostate Cancer: A Case Series of 9 Patients. J Nucl Med. 2022. PMID: 35835582. doi:10.2967/jnumed.122.263892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。